Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

SHPAX vs. SBHIX: which is better?

Bottom line

SHPAX vs SBHIX: the short answer

SHPAX and SBHIX are two share classes of the same fund — Health & Biotechnology Portfolio — so they hold the identical portfolio. The differences are cost, minimums and how you buy them.

SBHIX is cheaper at 2.6% vs 3% — a difference of $40 a year per $10,000 invested.

Over five years, SBHIX returned +4.7% a year vs +3.1% for SHPAX.

SHPAX has a front-end sales load of up to 5.75%; the other does not.

Updated Nov 19, 2026

SHPAX vs SBHIX side by side

SHPAXSBHIX
TypeMutual fundMutual fund
Fund familySaratoga AdvantageSaratoga Advantage
CategoryTechnology SectorTechnology Sector
Expense ratio3%2.6%
Annual cost per $10k$300$260
10-yr cost on $10k (prospectus)$3,702$2,934
Max front load5.75%0%
12b-1 fee——
1-yr return−5.5%+0.7%
5-yr return (annualized)+3.1%+4.7%
10-yr return (annualized)+4.1%+5.2%
Best quarter+15.0%+15.0%
Worst quarter−13.0%−13.0%
Net assets (fund)$10.5M$10.5M
Number of holdings2929
Portfolio turnover22%22%
Returns as ofDec 31, 2024Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearSHPAXSBHIXDifference
2024+0.3%+0.7%−0.4%
2023−0.4%+0.0%−0.4%
2022+2.0%+2.4%−0.4%
2021+16.7%+17.2%−0.5%
2020+3.6%+4.0%−0.4%
2019+16.2%+16.6%−0.4%
2018−5.5%−5.0%−0.4%
2017+12.0%+12.4%−0.4%
2016−2.0%−1.5%−0.4%
2015+6.9%+7.3%−0.4%

Source: Fund prospectus bar charts

FAQ

What is the difference between SHPAX and SBHIX?
SHPAX and SBHIX are two share classes of the same fund — Health & Biotechnology Portfolio — so they hold the identical portfolio. The differences are cost, minimums and how you buy them. SBHIX is cheaper at 2.6% vs 3% — a difference of $40 a year per $10,000 invested.
Which is cheaper, SHPAX or SBHIX?
SBHIX has the lower expense ratio (2.6%).
Should I own both SHPAX and SBHIX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.